Review in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Silvia ToricesDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.ORCID 0000-0001-8979-887X
Daniela Iglesias GalloDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.ORCID 0009-0004-9631-4641
Enrique LaraDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.ORCID 0009-0007-6919-5933
Sierra SimecekDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.
Sierra SimonDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.ORCID 0009-0004-9479-6560
Nykkie OkoroDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.
Sandy Del SolDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.
Michal ToborekDepartment of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, FL.ORCID 0000-0003-4475-2119
Funding
Tat, amyloid beta and brain endothelial barrier functionR01MH072567 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Michal Toborek · 2005 to 2026
$7.6M
Role of cerebral vasculature in brain ischemia in HIV infectionR01HL126559 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2014 to 2024
$3.8M
Targeting Inflammasomes in Substance Abuse and HIVR01DA050528 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2020 to 2024
$2.3M
Defining brain pericytes as a novel and myeloid-derived HIV reservoirR01MH128022 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2021 to 2025
$2.3M
Prevention of HIV and drug abuse-induced brain pathology by targeting mitochondriaR01DA044579 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2017 to 2021
$2.2M
Inflammasome Activation and Gut-Brain Axis Dysregulation in HIV and Methamphetamine-Associated DepressionR01DA059849 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Eleonore Beurel, Michal Toborek · 2024 to 2026
$1.7M
Adolescent exposure to PCBs as a risk factor for the development of depressionR01ES036983 · NIEHS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Eleonore Beurel, Michal Toborek · 2025 to 2026
$996k
Novel role of inflammasome activation in ART neurotoxicityR21MH122235 · NIMH · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TOBOREK, MICHAL · 2020 to 2021
$422k
CCL2/CCR2 modulates HIV-associated ischemic stroke by regulating blood brain barrier monocyte recruitmentR21NS141704 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI TORICES, SILVIA · 2024 to 2024
HIV-associated comorbidities, including cardiovascular and cerebrovascular events, are frequent diseases in people living with HIV. Notably, the prevalence of ischemic stroke is 3× higher in people living with HIV than in noninfected individuals, making it one of the most significant cerebrovascular events in people living with HIV. Despite this close association, the mechanisms involved in the enhanced incidence of ischemic stroke in HIV infection remain poorly understood. A chemokine CCL2 (C-C motif chemokine ligand 2), acting via its receptor CCR2 (C-C chemokine receptor type 2), is a prominent chemoattractant involved in the recruitment of CD4+T cells and monocytes/macrophages, which are primary targets for HIV infection. Due to its role in directing leukocyte migration into the brain and enhancing blood-brain barrier permeability, CCL2 is also a critical mediator of neuroinflammation after brain damage, such as ischemic stroke. In this review, we examine the role of the CCL2/CCR2 signaling pathway in HIV infection, its influence on the progression of ischemic stroke outcome and recovery, and propose the CCL2/CCR2 axis as a possible therapeutic target in people living with HIV.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting the CCL2/CCR2 Axis in HIV-1 Infection and Ischemic Stroke. · full record | OpenQuestion